Small-molecule radiopharmaceutical developer focused on oncology, creating an α-emitting PARP inhibitor (PARPi) radioligand therapy ([211At]PTT) in preclinical development with proof-of-concept in neuroblastoma and planned expansion to adult PARP-1 tumors. Offers a companion PET biomarker ([18F]FTT) advancing into Phase 2 breast cancer trials.